



Stage II Colon Cancer Case Study

ASSESS YOUR PATIENT'S IMMUNITY TO FIGHT CANCER




Maria, 52-year-old

- T4N0
- Moderately differentiated
- MSS Tumor
- Maria has an Immunoscore High

**Would you consider her a
candidate for chemotherapy?**

Prognostic Value of Immunoscore® in Stage II T4N0

Validated in Stage II T4N0 untreated patients (n=132) from the International SITC study. Patients with an Immunoscore High have Time To Recurrence Rate similar to low risk patients (89% - 5 years to recurrence).



Galon J, Hermitte F, Mlecnik B, et al., *J Clin Oncol*.2020; 38.15 (suppl; abstr 4105)

2 out of 3 T4N0 patients can be identified by Immunoscore® with a good prognosis and might be spared from chemotherapy



How can Immunoscore® help you manage stage II patients?

- Resolves patient recurrence risk
- Provides greater prognostic value than traditional measurements
- Guides treatment decision and improves patients management



THE IMMUNE RESPONSE
TO CANCER DIAGNOSTICS

CONTACT & FOLLOW US

HalioDx - Luminy Biotech Entreprises
163 Avenue de Luminy - 13009 Marseille - FRANCE
Phone: +33 (0) 4 91 29 30 90 - Fax: +33 (0) 4 91 29 30 99
✉ infos@haliodx.com



immunoscore-colon.com